摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3aR,10aS,10bR)-octahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(1H)-dione | 410535-69-2

中文名称
——
中文别名
——
英文名称
(3aR,10aS,10bR)-octahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(1H)-dione
英文别名
(1S,2R,6R)-5-oxa-10-azatricyclo[8.3.0.02,6]tridecane-4,11-dione
(3aR,10aS,10bR)-octahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(1H)-dione化学式
CAS
410535-69-2
化学式
C11H15NO3
mdl
——
分子量
209.245
InChiKey
RQKQXDRKITZZLF-HRDYMLBCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    439.3±34.0 °C(Predicted)
  • 密度:
    1.28±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    46.6
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Total Synthesis of Stemoamide, 9a-epi-Stemoamide, and 9a,10-epi-Stemoamide: Divergent Stereochemistry of the Final Methylation Steps
    作者:Imre Pápai、Petri M. Pihko、Juha H. Siitonen、Dániel Csókás
    DOI:10.1055/s-0040-1707201
    日期:2020.10
    Total syntheses of stemoamide, 9a-epi-stemoamide, and 9a,10-epi-stemoamide by a convergent A + B ring-forming strategy is reported. The synthesis required a diastereoselective late-stage methylation of the ABC stemoamide core that successfully enabled access to three of the four possible diastereomeric structures. For the natural stemoamide series, the diastereoselectivity can be rationalized both
    报道了通过收敛的 A + B 成环策略合成茎酰胺、9a-表-茎酰胺和 9a,10-表-茎酰胺。该合成需要对 ABC 茎酰胺核心进行非对映选择性后期甲基化,从而成功地获得四种可能的非对映体结构中的三种。对于天然茎酰胺系列,非对映选择性可以通过动力学和热力学参数来合理化,而对于天然 9a-表-茎酰胺系列,动力学选择性可以通过相关烯醇的预锥体化来解释。
  • Free-Radical Approaches to Stemoamide and Analogues
    作者:Nicolas Bogliotti、Peter I. Dalko、Janine Cossy
    DOI:10.1021/jo061628g
    日期:2006.12.1
    Two approaches allowing access to the tricyclic stemona backbone are presented. Both approaches rely on a free-radical cyclization reaction as the key step. In the formal synthesis of (±)-stemoamide, the construction of the A ring of the natural product was achieved via a 5-exo-trig radical cyclization with atom transfer. The two diastereoisomers issuing from this cyclization showed different reactivity
    提出了两种允许进入三环骨架的骨架的方法。两种方法都依赖于自由基环化反应作为关键步骤。在(±)-硬脂酰胺的形式合成中,天然产物的A环的构建是通过带有原子转移的5- exo - trig自由基环化而实现的。从该环化反应中产生的两种非对映异构体在形成最终产物的七元环时显示出不同的反应性。在这项研究的第二部分中,实现了7- exo - trig自由基环化,从而可以进入(±)-9,10-bis- epi-硬脂酰胺。该反应是高度立体选择性的,并允许控制分子中存在的四个连续的立体中心中的三个。
  • Total Synthesis of (−)-Stemoamide
    作者:Staffan Torssell、Emil Wanngren、Peter Somfai
    DOI:10.1021/jo070498o
    日期:2007.5.1
    A stereocontrolled total synthesis of (−)-stemoamide (1) is presented. The synthesis starts from commercially available (S)-pyroglutaminol (4). A chemoselective iodoboration of 5 was used to access key intermediate 3. The β,γ-unsaturated azepine derivative 2 was obtained via a Pd(0)-catalyzed sp2−sp3 Negishi cross-coupling using a Reformatsky nucleophile followed by a ring-closing metathesis reaction
    提出了立体控制的(-)-硬脂酰胺(1)的全合成。合成从可商购获得的(S)-焦谷氨醇(4)开始。5的化学选择性碘硼化用于访问关键中间体3。通过使用Reformatsky亲核试剂通过Pd(0)催化的sp 2 -sp 3 Negishi交叉偶联,然后进行闭环易位反应,获得了β,γ-不饱和氮杂环庚烷衍生物2。所需的C8-C9反式立体化学值为1,可通过立体选择性溴内酯化/ 1,4-还原序列获得。
  • Total Synthesis of (–)-Stemoamide by Sequential Overman/Claisen Rearrangement
    作者:Takaaki Sato、Noritaka Chida、Yasuaki Nakayama、Yuichiro Maeda、Naoto Hama
    DOI:10.1055/s-0035-1561948
    日期:——
    Overman/Claisen rearrangement of an allylic 1,2-diol is reported. The enantiopure allylic 1,2-diol was efficiently prepared from naturally occurring dimethyl tartrate. The chirality transfer reactions through two consecutive [3,3]-sigmatropic rearrangements proceeded with complete diastereoselectivity in a one-pot process. The enantioselective total synthesis of (–)-stemoamide using Overman/Claisen rearrangement
    摘要 报道了使用烯丙基1,2-二醇的Overman / Claisen重排的(-)-硬脂酰胺的对映选择性全合成。从天然存在的酒石酸二甲酯有效地制备了对映体纯的烯丙基1,2-二醇。通过两个连续的[3,3]-σ重排进行的手性转移反应在一锅法中以完全的非对映选择性进行。 报道了使用烯丙基1,2-二醇的Overman / Claisen重排的(-)-硬脂酰胺的对映选择性全合成。从天然存在的酒石酸二甲酯有效地制备了对映体纯的烯丙基1,2-二醇。通过两个连续的[3,3]-σ重排进行的手性转移反应在一锅法中以完全的非对映选择性进行。
  • Efficient total synthesis of (−)-stemoamide
    作者:Toshio Honda、Tomoha Matsukawa、Kazunori Takahashi
    DOI:10.1039/c0ob00850h
    日期:——
    An efficient diastereoselective synthesis of ()-stemoamide has been accomplished from a pyroglutamic acid derivative in eight steps and with 24% overall yield. The synthesis features an intramolecular samarium diiodide-promoted 7-exo-trigcyclization of a ketyl radical generated from the corresponding aldehyde.
    由焦谷氨酸衍生物分八步完成了(-)-硬脂酰胺的高效非对映选择性合成,总收率为24%。合成功能的分子内二碘化钐促进的7-外型- trig的从相应的醛产生的自由基一个羰游基的环化。
查看更多

同类化合物

金刚大碱 百部碱 新对叶百部碱 对叶百部碱 (7aR,8R,8aS,11S,11aS,11bR,11cR)-8-乙基十二氢-11-甲基-呋喃并[2,3-h]吡咯并[3,2,1-jk][1]苯并氮杂卓-10(2H)-酮 <3'S-<3'α,9'α(S*),9'aα>>-1',2',3',5',6',7',8'-octahydro-4-methyl-5-oxospiropyrrolo<1,2-a>azepin>-3'-carboxylic acid, hydrobromide salt <3'S-<3'α(S*),9'α(S*),9'aα>>-3'-(2,5-dihydro-4-methyl-5-oxo-2-furanyl)-1',2',3',5',6',7',8'-octahydro-4-methylspiropyrrolo<1,2-a>azepin>-5-one stemoamide (2S,4R,3'S,8'R,9a'S,2’’S,4’’S)-8'-methoxy-4-methyl-3’-(4-methyl-5-oxotetrahydrofuran-2-yl)octahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5(4H)-one tuberostemospiroline 2-oxostenine (3aR,10aR,10bR)-octahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(1H)-dione (3aR,9aS,9bR)-3a,6,8,9,9a,9b-Hexahydro-1H-3-oxa-6a-aza-cyclopenta[e]azulene-2,7-dione (2S,3'S,8'R,9a'S)-3'-tert-butyldiphenylsilyloxymethyl-8'-methoxy-1',2',3',7',8',9a'-hexahydro-5H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(6'H)-dione diethyl (2S,3'S,8'R,9a'S)-3'-tert-butyldiphenylsilyloxymethyl-8'-methoxy-5,5'-dioxo-1',2',3',5',6',7,'8',9a'-octahydro-5H-spiro{furan-2,9'-pyrrolo[1,2-a]azepin-4-yl}phosphonate (2S,4R,3'S,8'R,9a'S,2’’S)-8'-methoxy-4-methyl-3’-(4-methylene-5-oxotetrahydrofuran-2-yl)hexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione (2S,4R,3'S,8'R,9a'S,2’’R)-8'-methoxy-4-methyl-3’-(4-methylene-5-oxotetrahydrofuran-2-yl)hexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione (1R,2S,10R,12R,16R)-14,14-dimethyl-11,13,15-trioxa-6-azatetracyclo[8.6.0.02,6.012,16]hexadec-8-en-5-one 13-desmethyl-5-oxostenine (3aR,10aS)-1-methyl-3a,4,5,6,10,10a-hexahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(9H)-dione (1R,9R,10R,11S,14S,15S,16R)-14-methyl-10-prop-2-enyl-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadecane-5,13-dione 8-des-ethyl-(8S)-allyl-(-)-tuberostemonine didehydrotuberostemonine (-)-4-thiostenine (-)-4-oxostenine (3aR,10aS,10bS)-octahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(1H)-dione (+)-9a-epi-stemoamide (2S,4R,3'S,8'R,9a'S)-3'-hydroxymethyl-8'-methoxy-4-methylhexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione isoprotostemonine (1S,2S,3R,4R,6R)-3-hydroxy-4-methoxy-5-oxa-10-azatricyclo[8.3.0.02,6]tridecan-11-one (1S,3aR,7S,9aS,9bR)-1-methyl-7-((2S,4S)-4-methyl-5-oxotetrahydrofuran-2-yl)decahydro-3-oxa-6a-azacyclopenta[e]azulen-2-one 4-methoxy-3-methyl-5-[(2Z,3aR)-1t-methyl-8t-((2S)-4c-methyl-5-oxo-tetrahydrofuran-2r-yl)-(3ar,10at,10bt)-decahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepin-2-ylidene]-5H-furan-2-one 8-epi-stemoamide sessilifoliamide A (2R,3'S,8'R,9a'S)-3'-(tert-butyldiphenylsilyloxy)methyl-8'-methoxy-4-methylenehexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepin}-5,5'(4H,6'H)-dione (2R,3'S,8'R,9a'S)-8'-methoxy-4-methylene-3'-[(2S)-4-methylene-5-oxotetrahydrofuran-2-yl]hexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione (2R,3'S,8'R,9a'S)-3'-hydroxymethyl-5,5'-dioxo-8'-methoxy-4-methylenehexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepin}-(4H,6'H)-carbaldehyde (2R,3'S,8'R,9a'S,2''R)-8'-methoxy-4-methylene-3'-[(2S)-4-methylene-5-oxotetrahydrofuran-2-yl]hexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione (2R,3'S,8'R,9a'S)-3'-hydroxymethyl-8'-methoxy-4-methylenehexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepin}-5,5'(4H,6'H)-dione protostemonine (3S,9R,10R,11S,15R)-3-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]-10-prop-2-enyl-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadec-6-en-13-one Tuberostemonin (1R,4S,10R,11R,12R,15S,16S)-11-ethyl-15-hydroxy-15-methyl-4-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]-13-oxa-5-azatetracyclo[8.6.0.01,5.012,16]hexadecan-14-one (1R,3S,9R,10R,11S,14S,15S,16R)-3-[(2S)-4,4-dimethyl-5-oxooxolan-2-yl]-14-methyl-10-prop-2-enyl-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadecan-13-one (3S,9R,10R,11S,14S,15S,16R)-10-ethyl-14-methyl-3-[(2S,4R)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadecan-13-one (1S,2R,3S)-3-methyl-11-[(2S)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.3.0.02,6]tridecan-4-one (9R,10R,11S,14S,15S,16R)-10-ethyl-14-methyl-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadecan-13-one (10S,11S,14R,15R)-10-ethyl-14-methyl-3-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadeca-1(16),2-dien-13-one